Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT543 in Advanced Solid Tumors and Hematologic Malignancies
NCT03886831Phase 1Completed
- Sponsor
- Prelude Therapeutics
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of prt543 in solid tumor (advanced stage), diffuse large B-cell lymphoma (DLBCL), myelodysplastic syndrome (MDS) and 5 more, sponsored by Prelude Therapeutics. Primary endpoints: Dose Limiting Toxicities at Day 28, Maximally Tolerated Dose at 2 years and 1 more. Started Feb 2019; status: completed.
02
Drugs
prt543
03
Conditions
solid tumor (advanced stage)diffuse large B-cell lymphoma (DLBCL)myelodysplastic syndrome (MDS)myelofibrosis (MF)adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT03886831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03886831.